PME – Morgans rates the stock as Downgrade to Reduce

Morgans decreases the rating to Reduce from Hold after the share price has risen by over 35% in the last month to record highs. In the absence of news, it’s felt this may be due to unwinding of short positions in the stock, (down to circa 3.5% from over 5% in January).

While the broker increases the target price to $49.69 from $41.30, current prices are considered unsustainable in the short term. The analyst suggests trimming heavily overweight positions and looking for a better entry point (below $45.00) into this quality name.

Morgans makes no changes to forecasts. The company will post its full year FY21 result in mid-August.

Sector: Health Care Equipment & Services.

 

Target price is $49.69.Current Price is $53.20. Difference: ($3.51) – (brackets indicate current price is over target). If PME meets the Morgans target it will return approximately -7% (excluding dividends, fees and charges – negative figures indicate an expected loss).

 

 

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →